Investigating Emotional Effects of GLP-1 Medications

Some users of GLP-1 weight loss and diabetes medications have reported experiencing emotional flattening and reduced pleasure from activities they previously enjoyed—a phenomenon some have informally called the "Ozempic personality."

Medical professionals report an increase in patient accounts of these psychological effects. Researchers are investigating potential links to the brain's reward system, though the underlying causes and prevalence are not yet fully understood.

Reported Patient Experiences

Multiple sources describe a phenomenon where users feel a diminished emotional response.

Korrie Stevenson, a 51-year-old from Winter Park, Florida, reported experiencing emotional flatness within months of starting a GLP-1 medication in 2023. By 2025, she described this progressing to apathy that interfered with daily tasks, such as missing administrative deadlines. In January 2026, she reduced her weekly Zepbound dosage from 15mg to 12.5mg and reported a return of positive emotions, including feeling joy, within two weeks.

Summer Kessel, a registered dietitian who works with patients on GLP-1 medications, stated she has heard similar accounts from clients. Kessel also reported experiencing comparable emotional effects personally after more than three years on the medications.

Reported descriptions of the effect include:

• A feeling of being unable to fully connect to exciting or enjoyable moments.
• A general sense of apathy or emotional "flatness."
• Some users have stated they did not recognize the symptom as potentially medication-related until hearing others describe similar experiences.

Medical and Research Perspectives

The psychological impacts of GLP-1 drugs are less studied than their physical effects, which primarily relate to weight loss and diabetes management.

Researchers are examining how these medications might interact with the brain's dopamine reward system, but findings and theories are not consistent.

• Daniel Drucker, an obesity researcher at Mount Sinai Hospital in Toronto, has suggested GLP-1 drugs may "tone down" activity in brain regions associated with pleasure.
• Zak Krumm, a researcher at the University of Florida, has conducted animal studies indicating that GLP-1 medications can chronically mute responses to rewards.
• Other research cited in the reports has shown conflicting results, with some studies indicating these drugs might enhance dopamine signaling.

The exact pharmacological mechanisms remain unclear. Researchers are also uncertain whether the reported emotional effects are purely biological or if psychological factors related to significant weight loss and changes in identity or lifestyle may contribute.

Reported Management and Response

Some medical professionals and patients have reported methods for addressing these emotional effects.

• Dosage Adjustment: Physician Nicholas Nadolsky, who is compiling case studies on the phenomenon, has observed that reducing the medication dosage can resolve symptoms for some patients within weeks.
• Antidepressants: Some users have reported turning to antidepressant medications to counteract the emotional flattening.

The drugs remain generally considered safe for their approved uses, but the reports highlight an area requiring further clinical investigation.

Status of Research and Next Steps

The understanding of this reported side effect is in a preliminary phase.

• Researchers, including Zak Krumm and Nicholas Nadolsky, are continuing to compile and analyze case studies to better characterize the phenomenon.
• Significant further study is needed to determine how common these emotional effects are, establish clear causation, and develop any necessary treatment or management strategies.

As the use of GLP-1 medications for weight management expands, understanding their full impact on quality of life, including potential psychological effects, is considered an important area for ongoing research.